Vice President of Information Technology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It’s an exciting time to be part of Team Olema, with our transformation into a fully integrated oncology company well underway, top-line data from our lead program expected later this year, and our first potential commercial launch on the horizon.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in the fall which, if successful, could lead to our first potential approval and commercial launch in 2027. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant has the potential to transform the metastatic breast cancer treatment paradigm and access a $15 billion global market opportunity.
Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently reported encouraging Phase 1 monotherapy data from this program across multiple solid tumor types and are advancing patient enrollment in the ongoing combination arms in MBC.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and a passionate team dedicated to helping the patients we serve feel better, longer. We possess a deep commitment to our shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
About the Role >>> Vice President of Information Technology
The Vice President of Information Technology will serve as Olema’s senior technology leader and will own the strategy, security, and day-to-day operations and delivery of the global IT function. This leader will identify, build, and refine the new and existing systems, technology, tools, cybersecurity, and artificial intelligence capabilities the business requires as we advance our programs and toward our first potential product approval and commercial launch in the US.
The role will partner closely with leaders across the business, including Commercial, Medical Affairs, Regulatory Affairs, Quality, Clinical Development, Pharmacovigilance, Manufacturing and Supply Chain, and G&A. The ideal candidate will combine hands-on IT experience and leadership, deep Microsoft and O365 expertise, and demonstrable commercial launch experience with a strong enterprise-wide mindset and sound judgment in a fast-paced, highly regulated environment. This individual must also be an AI-forward leader and strong advocate for the rapid, responsible implementation of AI tools and frameworks to improve decision-making, productivity, service delivery, and organizational scalability.
This position is based in Olema’s San Francisco office and will require regular travel to Boston and Ireland, as needed.
Your work will primarily encompass:
Enterprise IT Strategy
Define and execute a multi-year enterprise IT strategy and applications roadmap aligned with business goals across research, development, commercial, and corporate functions.
Set efficient and scalable architecture, integration, cloud, SaaS, data, and technology lifecycle standards that support growth without unnecessary complexity.
Establish a strategic and effective IT operating model, including internal capabilities, outsourced services, governance, and decision rights.
Establish disciplined intake, prioritization, funding, and delivery processes that make value, cost, risk, capacity, and dependencies visible.
Advise the Executive Committee on technology investments, performance, cybersecurity, and